As of 23 April 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of iopromide (1) 623.40 mg/mL (equivalent to 300 mg iodine) and (2) 768.86 mg/mL (equivalent to 370 mg iodine) in 500 mL in clear glass infusion bottle for use as radiocontrast media. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 23 April to 08 May 2026.

Based on current evidence, as preliminary recommendation, the HTA Council recommends the government financing of the following:

• Iopromide  623.40 mg/mL (equivalent to 300 mg iodine), 500 mL clear glass infusion bottle; and,
• Iopromide 768.86 mg/mL (equivalent to 370 mg iodine),  500mL clear glass infusion bottle. 

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 08 May 2026 (Friday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.